<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02140242</url>
  </required_header>
  <id_info>
    <org_study_id>TUD-2DAUNO-058</org_study_id>
    <nct_id>NCT02140242</nct_id>
  </id_info>
  <brief_title>Comparison Between Two Dose Levels of Daunorubicin and Between One vs. Two Induction Cycles for Adult Patients With AML</brief_title>
  <acronym>DaunoDouble</acronym>
  <official_title>Randomized Comparison Between Two Dose Levels of Daunorubicin and Between One Versus Two Cycles of Induction Therapy for Adult Patients With Acute Myeloid Leukemia ≤65 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universitätskrebszentrum des Universitätsklinikums</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Masaryk University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed trial will address two clinically important questions for younger patients with
      newly diagnosed acute myeloid leukemia (AML): the optimal dose of daunorubicin in induction
      therapy and the necessity of a second induction cycle in patients with a good response after
      the first induction. The primary endpoint is the rate of good responders. Secondary outcomes
      will be relapse-free survival, overall survival and minimal residual disease kinetics.
      Patients will be recruited in about 40 treatment centers of the Study Alliance Leukemia study
      group over a period of 40 months. The results will be of great clinical relevance: First, the
      study could facilitate the establishment or confirmation of the optimal daunorubicin dose.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the first part of the trial, patients will be randomly assigned to receive either 90 mg/m2
      or 60 mg/m2 daunorubicin in the first induction cycle in addition to standard dosed
      cytarabine. Assuming a superiority of 90 mg/m2, 436 patients will be recruited. In the second
      part of the trial, good responders will be randomized to receive either a second or no
      further induction cycle. Assuming a non-inferiority of the single induction regarding the
      rate of complete remissions, a number of 360 patients will be included in the second part.
      Furthermore, in case of a non-inferiority of single versus double induction in good
      responders, about half of all younger AML patients could be spared a second induction cycle,
      leading to a reduction in treatment-related mortality, fewer days spent in hospital and
      improved quality of life.

      As a result of the preplanned interim analysis of part I, the sponsor decided to suspend
      randomization in trial part I and to offer all patients the standard dose of 60 mg/m2
      daunorubicin in both induction cycles (part I and II of the trial). Because of this an
      Amendment was sent to and approved by regulatories and ethics comitee.

      The inclusion age was raised to 65 years based on the current German treatment guidelines in
      which patients up to the age of 65 are considered eligible for intensive induction
      chemotherapy with DA60 [Onkopedia-Leitlinie 2017].
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 16, 2014</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response rate after first induction</measure>
    <time_frame>day 15</time_frame>
    <description>To investigate whether a higher dose of daunorubicin in induction chemotherapy leads to an increase in hematological good responders defined as having &lt;5% myeloid blasts on day 15 after start of induction therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate complete remissions</measure>
    <time_frame>day 35 after final induction</time_frame>
    <description>To investigate whether the rate of complete remissions (CR) after single induction is similar to that after double induction in patients with good response to induction I.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>rate cytogenetic and molecular complete remissions</measure>
    <time_frame>day 35</time_frame>
    <description>To investigate whether a higher dose of daunorubicin in induction chemotherapy will lead to an increase in cytogenetic and molecular complete remissions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>event-free survival (EFS)</measure>
    <time_frame>5 years</time_frame>
    <description>To investigate whether a higher dose of daunorubicin will lead to improved event-free survival (EFS), relapse-free survival (RFS) and overall survival (OS). To investigate whether EFS, RFS and OS are similar after single versus double induction in patients with good response to induction I.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relapse-free survival (RFS)</measure>
    <time_frame>5 years</time_frame>
    <description>To investigate whether a higher dose of daunorubicin will lead to improved event-free survival (EFS), relapse-free survival (RFS) and overall survival (OS). To investigate whether EFS, RFS and OS are similar after single versus double induction in patients with good response to induction I.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>5 years</time_frame>
    <description>To investigate whether a higher dose of daunorubicin will lead to improved event-free survival (EFS), relapse-free survival (RFS) and overall survival (OS). To investigate whether EFS, RFS and OS are similar after single versus double induction in patients with good response to induction I.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between Minimal Residual Disease (MRD) and EFS, RFS, OS</measure>
    <time_frame>day 35</time_frame>
    <description>To correlate the level of cytogenetic and molecular minimal residual disease after induction treatment with survival outcomes EFS, RFS and OS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of induction deaths</measure>
    <time_frame>day 60</time_frame>
    <description>Rate of induction deaths (until day 60 or beginning of consolidation treatment - whichever occurs first)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious infectious complications</measure>
    <time_frame>day 35</time_frame>
    <description>Incidence of serious infectious complications Grades 3-4 (Common Toxicity Criteria for Adverse Effects (CTCAE) V4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sonographic cardiac left ventricular ejection fraction</measure>
    <time_frame>day 35</time_frame>
    <description>Sonographic cardiac left ventricular ejection fraction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of pro-brain natriuretic peptide (por-BNP) and Troponin-T</measure>
    <time_frame>day 35</time_frame>
    <description>Serum levels of pro-BNP and Trop-T</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of CTCAE grade ≥3 cardiac complications</measure>
    <time_frame>day 35</time_frame>
    <description>Incidence of CTCAE grade ≥3 cardiac complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of early deaths</measure>
    <time_frame>week 2</time_frame>
    <description>Rate of early deaths (2 weeks)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Leukemia, Myelocytic, Acute</condition>
  <arm_group>
    <arm_group_label>daunorubicin 60 mg/m2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>study part 1 - dose daunorubicin standard dose daunorubicin in induction 1 (60 mg/m2) on days 3-5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double induction</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>study part 2: induction cycles double induction (only patients with good response)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single induction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>study part 2: induction cycles single induction (only patients with good response)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>study part 1 - dose daunorubicin</intervention_name>
    <description>standard induction dose of daunorubicin 60 mg/m2 on days 3-5</description>
    <arm_group_label>daunorubicin 60 mg/m2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>induction cycles</intervention_name>
    <description>single induction cycle versus double induction cycles (only patients with good response after first induction) Allocation is randomized for cytogenetic risk.</description>
    <arm_group_label>Double induction</arm_group_label>
    <arm_group_label>Single induction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed AML other than acute promyelocytic leukemia (APL) according to WHO
             criteria, i.e. bone marrow aspirate or biopsy must contain ≥20% blasts of all
             nucleated cells or differential blood count must contain ≥20% blasts. In acute
             erythroid leukemia, ≥20% blasts in all non-erythroid bone marrow cells. In AML defined
             by cytogenetic aberrations, the rate of blasts may be &lt;20%. Secondary AMLs are
             eligible for inclusion.

          -  Age 18- inkl.65 years

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Adequate liver and renal function as assessed by the following laboratory requirements
             to be conducted within 7 days prior to screening:

               -  Total bilirubin ≤ 1.5 times the upper limit of normal

               -  alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 2.5 times upper
                  limit of normal

               -  Creatinine ≤ 1.5 times upper limit of normalExclusion Criteria:

          -  Adequate cardiac function, i.e. left ventricular ejection fraction (LVEF) of ≥ 50% as
             assessed by transthoracic two-dimensional echocardiography (&quot;M Mode&quot;) or multiple
             gated acquisition scan (MUGA scan)

          -  Signed informed consent

          -  Women must fulfill at least one of the following criteria in order to be eligible for
             trial inclusion:

               -  Post-menopausal (12 months of natural amenorrhea or 6 months of amenorrhea with
                  Serum follicle stimulating hormone (FSH) &gt; 40 U/ml)

               -  Postoperative (i.e. 6 weeks) after bilateral ovariectomy with or without
                  hysterectomy

               -  Continuous and correct application of a contraception method with a Pearl Index
                  of &lt;1% (e.g. implants, depots, oral contraceptives, intrauterine device - IUD).

               -  Sexual abstinence

               -  Vasectomy of the sexual partner

        Exclusion criteria:

          -  Patients who are not eligible for standard chemotherapy as assessed by the treating
             physician

          -  Central nervous system manifestation of AML

          -  Cardiac disease: i.e. heart failure New York Heart Association (NYHA) III or IV;
             unstable coronary artery disease (MI more than 6 months prior to study entry is
             permitted); serious cardiac ventricular arrhythmias requiring anti-arrhythmic therapy

          -  Patients undergoing renal dialysis

          -  Chronic pulmonary disease with clinical relevant hypoxia

          -  Known HIV or Hepatitis infection

          -  Uncontrolled active infection

          -  Medical conditions other than AML with an estimated life expectancy below 6 months

          -  Previous treatment of AML except hydroxyurea up to 5 days

          -  Relapsed or primary refractory AML

          -  Acute promyelocytic leukemia

          -  Previous anthracycline-containing chemotherapy

          -  Treatment with any known non-marketed drug substance or experimental therapy within 4
             weeks prior to enrollment

          -  Incapability of understanding purpose and possible consequences of the trial

          -  Pregnant or breastfeeding women

          -  Evidence suggesting that the patient is not likely to follow the study protocol (e.g.
             lacking compliance)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Röllig, PD Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Dresden Carl Gustav Carus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frank Staps</last_name>
    <phone>+049 - 0351 458 5198</phone>
    <email>frank.staps@uniklinikum-dresden.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Annett Haake</last_name>
    <phone>+049 - 0351 458 3965</phone>
    <email>annett.haake@uniklinikum-dresden.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Interní klinika LF Masarykovy univerzity a Fakultní nemocnice Brno</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jirí Mayer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Faculty Hospital Hradec Králové, II. Clinic of international medicine</name>
      <address>
        <city>Hradec Králové</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pavel Zák, doc. MUDr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultní nemocnice Olomouc</name>
      <address>
        <city>Olomouc</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomas Szotkowski, Doc. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultní nemocnice Královské Vinohrady</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Novák, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ústav hematologie a krevní transfuze (ÚHKT)</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jolana Mertová, MUDr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniklinik RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edgar Jost, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Altenburger Land GmbH</name>
      <address>
        <city>Altenburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armin Schulz-Abelius, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Sozialstiftung Bamberg Klinikum am Bruderwald</name>
      <address>
        <city>Bamberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martina Teichmann, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charite Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Baldus, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Bielefeld</name>
      <address>
        <city>Bielefeld</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Görner, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Augusta Kliniken Bochum Hattingen</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dirk Behringer, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ev. Diakonie-Krankenhaus gGmbH Bremen</name>
      <address>
        <city>Bremen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes Kullmer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Chemnitz GmbH</name>
      <address>
        <city>Chemnitz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathias Hänel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>PD Dr. Christoph Röllig</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christoph Röllig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Düren gem. GmbH</name>
      <address>
        <city>Düren</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Flaßhove, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marienhospital Düsseldorf GmbH</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aristoteles Giagounidis, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Krause, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Noppeney, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johann Wolfgang Goethe-Universität Frankfurt am Main</name>
      <address>
        <city>Frankfurt am Main</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Björn Steffen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle (Saale)</name>
      <address>
        <city>Halle</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maxi Wass, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>St. Marien-Hospital Hamm</name>
      <address>
        <city>Hamm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heinz Albert Dürk, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alwin Krämer, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Bernward Krankenhaus Hildesheim</name>
      <address>
        <city>Hildesheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrich Kaiser, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastian Scholl, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Westpfalz-Klinikum GmbH</name>
      <address>
        <city>Kaiserslautern</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Mahlmann, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Städtisches Krankenhaus Kiel</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastian Buske, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftsklinikum Mittelrhein GmbH</name>
      <address>
        <city>Koblenz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dirk Niemann, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen und Marburg</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Neubauer, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Schliemann, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg-Nord</name>
      <address>
        <city>Nürnberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerstin Schäfer-Eckart, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Agaplesion Diakoniekrankenhaus Rotenburg</name>
      <address>
        <city>Rotenburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Heits, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diakonie-Klinikum Schwäbisch Hall gGmbH</name>
      <address>
        <city>Schwäbisch Hall</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Geer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Sindelfingen-Böblingen</name>
      <address>
        <city>Sindelfingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Ritter, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Robert-Bosch-Krankenhaus</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Kaufmann, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rems-Murr-Klinikum Winnenden</name>
      <address>
        <city>Winnenden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefani Parmentier, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.uniklinikum-dresden.de/</url>
    <description>University Hospital</description>
  </link>
  <link>
    <url>http://www.czecrin.net/</url>
    <description>czech ECRIN center</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2014</study_first_submitted>
  <study_first_submitted_qc>May 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2014</study_first_posted>
  <last_update_submitted>August 10, 2017</last_update_submitted>
  <last_update_submitted_qc>August 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>leukemia</keyword>
  <keyword>induction treatment</keyword>
  <keyword>daunorubicin</keyword>
  <keyword>7+3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Daunorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

